Ascentage Pharma (06855) has announced that on October 27, 2026, the trustee purchased a total of 200,000 existing shares on the market for the purposes of the 2022 Restricted Share Unit Plan, in order to satisfy restricted share units upon vesting.
The shares were acquired on-market by the trustee under the 2022 Restricted Share Unit Plan and will be used to meet restricted share unit obligations when those units vest.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments